Table 1.
Patient baseline characteristics.
| All patients (n = 96) | Maximal myelosuppressive toxicity | |||||||
|---|---|---|---|---|---|---|---|---|
| High toxicity (n = 54) | Intermediate (n = 8) | Low toxicity (n = 34) | ||||||
| Gender, N (%) | ||||||||
| Male | 47 | (49.0%) | 26 | (48.1%) | 3 | (37.5%) | 18 | (52.9%) |
| Female | 49 | (51.0%) | 28 | (51.9%) | 5 | (62.5%) | 16 | (47.1%) |
| Age, in years, median (range) | ||||||||
| All | 65.5 | (47–82) | 67 | (51–82) | 64 | (47–76) | 63 | (48–76) |
| Male | 68 | (51–82) | 69 | (57–82) | 64 | (56–74) | 61 | (51–76) |
| Female | 63 | (47–80) | 64 | (51–80) | 64 | (47–76) | 63 | (48–76) |
| Clinical stage, N (%) | ||||||||
| Stage I | 17 | (17.7%) | 12 | (22.2%) | 2 | (25.0%) | 3 | (8.8%) |
| Stage II | 11 | (11.5%) | 7 | (13.0%) | – | – | 4 | (11.8%) |
| Stage III | 34 | (35.4%) | 15 | (27.8%) | 2 | (25.0%) | 17 | (50.0%) |
| Stage IV | 32 | (33.3%) | 18 | (33.3%) | 4 | (50.0%) | 10 | (29.4%) |
| Not specified | 2 | (2.1%) | 2 | (3.7%) | – | – | – | – |
| Histological classifications, N (%) | ||||||||
| Adenocarcinoma (AC) | 58 | (60.4%) | 34 | (63.0%) | 5 | (62.5%) | 19 | (55.9%) |
| Squamous cell carcinomas (SCC) | 19 | (19.8%) | 10 | (18.5%) | 1 | (12.5%) | 8 | (23.5%) |
| Non-small cell lung cancer (NSCLC) | 13 | (13.5%) | 8 | (14.8%) | – | – | 5 | (14.7%) |
| Large cell carcinoma (LLC) | 6 | (6.3%) | 2 | (3.7%) | 2 | (25.0%) | 2 | (5.9%) |
| Smoking history, N (%) | ||||||||
| Current | 40 | (41.7%) | 18 | (33.3%) | 4 | (50.0%) | 18 | (52.9%) |
| Former | 46 | (47.9%) | 30 | (55.6%) | 4 | (50.0%) | 12 | (35.3%) |
| Never | 10 | (10.4%) | 6 | (11.1%) | – | – | 4 | (11.8%) |